- Tytuł:
- Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial
- Autorzy:
- Źródło:
- In eClinicalMedicine November 2023 65
Czasopismo naukowe